Table 2.
Efficacy and adverse event data for postoperative gynaecology studies.
| Outcomes | Percent with outcome | Risk ratio (95% CI) | NNT, NNTp, or NNH (95% CI) | Comparison with aspirin 650 mg | |
|---|---|---|---|---|---|
| Drug and dose | Active | Placebo | |||
| At least 50% maximum pain relief (TOTPAR) | |||||
| Diclofenac-K 50 mg | 60 | 17 | 3.6 (2.5 to 5.2) | 2.3 (1.9 to 3.0) | ∗ p=0.044 |
| Diclofenac-K 100 mg | 56 | 17 | 3.4 (2.3 to 4.9) | 2.5 (2.0 to 3.4) | p=0.13 |
| Aspirin 650 mg | 46 | 17 | 2.8 (1.9 to 4.1) | 3.5 (2.6 to 5.2) | |
| Global evaluation—“very good or excellent” | |||||
| Diclofenac-K 50 mg | 59 | 13 | 4.4 (2.9 to 6.7) | 2.2 (1.8 to 2.8) | ∗ p=0.0023 |
| Diclofenac-K 100 mg | 54 | 13 | 4.0 (2.7 to 6.1) | 2.5 (2.0 to 3.2) | ∗ p=0.021 |
| Aspirin 650 mg | 38 | 13 | 2.9 (1.8 to 4.5) | 4.0 (2.9 to 6.4) | |
| Patients who remedicate within 8 hours | NNTp | ||||
| Diclofenac-K 50 mg | 37 | 71 | 0.5 (0.4 to 06) | 2.9 (2.2 to 4.2) | ∗ p=0.0061 |
| Diclofenac-K 100 mg | 39 | 71 | 0.5 (0.4 to 0.7) | 3.1 (2.3 to 4.5) | ∗ p=0.012 |
| Aspirin 650 mg | 58 | 71 | 08 (0.7 to 0.9) | 7.4 (4.2 to 34) | |
| Patients experiencing any adverse event | NNH | ||||
| Diclofenac-K 50 mg | 8 | 5 | 1.5 (0.6 to 3.4) | Not calculated | |
| Diclofenac-K 100 mg | 6 | 5 | 1.2 (0.5 to 2.9) | Not calculated | |
| Aspirin 650 mg | 9 | 5 | 1.9 (0.8 to 4.3) | Not calculated | |
Note: comparisons were carried out using a two-tailed z-test (Tramer et al. [1]). ∗statistical significance; NNT = number needed to treat for one to benefit; NNTp = number needed to treat to prevent one event; NNH = number needed to treat for one to be harmed.